{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:46:18Z","timestamp":1780389978531,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS). Differently from ocrelizumab, that is administered intravenously, ofatumumab if the first anti-CD20 mAb to be administered subcutaneously without a premedication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and objectives<\/jats:title><jats:p>In this study we aimed to describe and compare the main characteristics of Individual Case Safety Reports (ICSRs) describing the occurrence of Injective Related Reactions (IRRs) following the treatment with ocrelizumab and ofatumumab reported in the Eudravigilance (EV) database during years 2021\u20132023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 860 ICSRs with either ofatumumab and ocrelizumab as suspected drug were retrieved from Eudravigilance, of which 51% associated with ofatumumab and 49% with ocrelizumab. The majority of patients who experienced IRRs following ocrelizumab belonged to the age group of 18\u201364\u2009years (73%), while the age-group was mostly not specified (55%) in ICSRs reporting ofatumumab as suspected. The distribution of gender was almost similar in the two groups, with the majority of ICSRs related to female patients. \u201cPyrexia\u201d was the Preferred Term (PT) most reported for ofatumumab, while \u201cInfusion related reaction\u201d were more frequently reported with ocrelizumab. Premedication drugs were reported in 148 ICSRs. Out of 89 ICSRs for which the Time to Event (TTE) was calculated, 74 reported IRRs that occurred the same day of the drug administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Based on the results of this study, although a risk of ofatumumab-induced IRRs cannot be excluded, it should be considered as manageable considering that the drug seems to be mostly associated with the occurrence of fever. Thus, it is important to continue to closely monitor the use of these in clinical practice to improve the knowledge on their long-term safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1383910","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:23:24Z","timestamp":1719462204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Cristina","family":"Scavone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Anatriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Baccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Giulio Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Moreggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.3390\/jcm11226855","article-title":"The safety profile of COVID-19 vaccines in patients diagnosed with multiple sclerosis: a retrospective observational study","volume":"11","author":"Maniscalco","year":"2022","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.3390\/jcm12134236","article-title":"Three doses of COVID-19 vaccines: a retrospective study evaluating the safety and the immune response in patients with multiple sclerosis","volume":"12","author":"Maniscalco","year":"2023","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/ph13120466","article-title":"Preliminary results of the FASM study, an on-going Italian active pharmacovigilance project","volume":"13","author":"Maniscalco","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives","volume":"18","author":"D'Amico","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/14740338.2017.1388371","article-title":"Drugs approved for the treatment of multiple sclerosis: review of their safety profile","volume":"16","author":"Auricchio","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","volume-title":"Kesimpta: assessment report","year":""},{"key":"ref10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.2546","article-title":"Injection-related reactions with subcutaneous Administration of Ofatumumab in relapsing multiple sclerosis: data from clinical studies and post marketing experience (P7-4.011)","volume":"98","author":"Kramer","year":"2022","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5\u2009years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10354-022-00939-w","article-title":"An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis","volume":"172","author":"Ovchinnikov","year":"2022","journal-title":"Wien Med Wochenschr"},{"key":"ref16","year":""},{"key":"ref17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries: their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf"},{"key":"ref19","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ICH harmonised tripartite guideline post-approval safety data management: definitions and standards for expedited reporting E2D","year":""},{"key":"ref20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.410430409","article-title":"Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination","volume":"43","author":"Storch","year":"1998","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm1714","article-title":"Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis","volume":"14","author":"Obermeier","year":"2008","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/brain\/awh486","article-title":"Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis","volume":"128","author":"Cepok","year":"2005","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J Clin Invest"},{"key":"ref27","volume-title":"Ocrevus: annex I summary of product characteristics","year":""},{"key":"ref28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"Sanchez-Felix","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/imm.13004","article-title":"Impact of sex hormones on immune function and multiple sclerosis development","volume":"156","author":"Ysrraelit","year":"2019","journal-title":"Immunology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.msard.2022.104103","article-title":"The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades","volume":"68","author":"Romero-Pinel","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/ph16081071","article-title":"Hepatobiliary adverse reactions during treatment with cladribine: analysis of data from the European spontaneous reporting system","volume":"16","author":"Veli\u0219cu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref32","first-page":"529","article-title":"Gender differences in pharmacokinetics and pharmacodynamics","volume":"37","author":"Beierle","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ph15030298","article-title":"A sex-and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases","volume":"15","author":"Brabete","year":"2022","journal-title":"Pharmaceuticals"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1023\/B:RIAN.0000005926.03250.c0","article-title":"Gender differences in risk perception: theoretical and methodological perspectives","volume":"18","author":"Gustafson","year":"1998","journal-title":"Risk Anal"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/heapro\/dat063","article-title":"Gender differences in health information behaviour: a Finnish population-based survey","volume":"30","author":"Ek","year":"2015","journal-title":"Health Promot Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"CD013247","DOI":"10.1002\/14651858.CD013247.pub2","article-title":"Ocrelizumab for multiple sclerosis","volume":"2022","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"OC investigators Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12360-x","article-title":"Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study","author":"Zangh\u00ec","year":"2024","journal-title":"J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"550201","DOI":"10.3389\/fpsyt.2020.550201","article-title":"We really need clear guidelines and recommendations for safer and proper use of aripiprazole and risperidone in a pediatric population: real-world analysis of EudraVigilance database","volume":"11","author":"Rafaniello","year":"2020","journal-title":"Front Psych"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40264-020-01021-3","article-title":"PCSK9 inhibitors and neurocognitive adverse drug reactions: analysis of individual case safety reports from the Eudravigilance database","volume":"44","author":"di Mauro","year":"2021","journal-title":"Drug Saf"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/BF03261977","article-title":"Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review","volume":"35","author":"Inch","year":"2012","journal-title":"Drug Saf"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13098","article-title":"The value of patient reporting to the pharmacovigilance system: a systematic review","volume":"83","author":"In\u00e1cio","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/ph16111611","article-title":"Skin toxicities associated with botulin toxin injection for aesthetic procedures: data from the european spontaneous reporting system","volume":"16","author":"Nicoletti","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fphar.2017.00607","article-title":"Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania region (Italy): BIO-cam observational study","volume":"8","author":"Scavone","year":"2017","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1383910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:23:30Z","timestamp":1719462210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1383910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":44,"alternative-id":["10.3389\/fneur.2024.1383910"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1383910","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"article-number":"1383910"}}